The last century has seen a revolution in mod ern medicine with the discovery of many new treatments for common diseases. However, inter individual variation means that response to treat ment varies widely, rendering a 'onesizefitsall' approach to patient care increasingly obsolete. With the completion of the human genome sequencing project and nextgeneration sequenc ing technologies, as well as advances in technol ogy for the 'omics' approaches (e.g., genomics, proteomics and metabolomics), the pharma ceutical blockbuster model is gradually being challenged by a personalized medicine (PM) model. PM can be considered as the stratification of patient groups based on the molecular ana lysis of genes, proteins and metabolites. PM tests, or 'theranostics', can be developed as companion tests with pharmaceutical partners or as stand alone tests for diagnostic or prognostic purposes. PM is enabling a paradigm shift from a treat mentcentered health system to a comprehensive patientcentered care management approach with potentially enhanced efficacy and reduced adverse events. As illustrated in Figure 1 , the high cost of adverse events has previously been esti mated annually in the USA at US$177 billion per year and drugs overall have efficacy only approxi mately 50% of the time, representing a potential waste of approximately $350 billion of the world wide $700 billion or more drug spend [1] . In addi tion to the wellknown Herceptin ® story, poten tially highimpact examples of the clinical utility of PM include the use of KRAS testing to identify mutants unlikely to respond to largemolecule EGF receptor (EGFR) inhibitors, which could save the US health system $600 million annu ally [2] and, perhaps, the influence of CYP2C9/ VKORC1 genotypes on warfarin metabolism. While the latter scenario is still under investi gation, and ultimate utility would be subject to complex realworld prescription and workflow dynamics, it has been suggested that integration of a genetic warfarin test could avoid 85,000 serious bleeding events and 17,000 strokes [101] , providing an annual saving of $1.1 billion in the USA. Such examples highlight the health-eco nomic potential of the field of PM, in addition to the obvious clinical advantages.
While the USA reimbursement environment for clinical diagnostics presents many challenges for the value capture for test innovators, several high value medical diagnostics are currently reimbursed by the US Centers for Medicare and Medicaid (Medicare) and commercial payers. These tests are typically reimbursed by payers in one of two ways. First, diagnostic reference laboratories can file claims using stacked Current Procedure Terminology (CPT) codes that describe generic laboratory procedures such as 'amplification, tar get, each nucleic sequence', and be paid based on a technical costderived fee schedule. This 'cost based' approach does not explicitly reward the unique value that an innovative test may offer. The other approach to reimbursement is 'valuebased',
The clinical utility and medico-economic value of several personalized diagnostic tests has been well described in the literature. Development of such tests, including generation of the necessary supportive clinical validation data, is a complex and expensive endeavor. In general, sponsors of such tests lack sufficient clarity on appropriate reimbursement and regulatory pathways to provide the clear development framework necessary to incentivize the required level of investment. In the USA, an imperfect reimbursement paradigm has evolved to accommodate a small number of 'value-priced' laboratory-developed tests, although major structural barriers remain to broader implementation. In Europe, by contrast, there is virtually no precedent for value-based public sector pricing, and even such procedurally based pricing as currently exists is administered by a complex network of largely decentralized bodies. As a consequence, patient access is limited and health-economic savings are not realized. This article explores some of the European market entry barriers, with a focus on reimbursement challenges, and highlights some collaborative proposals to address such.
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and generally relies on the use of 'not otherwise listed codes', or catch all miscellaneous CPT codes that result in payment that is unique to the value of the specific test performed. This second approach in particular has resulted in test reimbursements of several thousand dollars for certain complex tests (e.g., Oncotype DX ® breast cancer assay from Genomic Health Inc., CA, USA). While costeffectiveness may or may not be considered by pay ers in their rationale for paying for these highvalue tests (Medicare has historically been restricted from using cost-effectiveness data when making coverage determinations), for many payers, the cost impact is influential, particularly if use of the test results in direct cost savings such as avoid ance of inappropriate drug therapy. Furthermore, initiatives such as Senator Orrin Hatch's proposed legislation regarding a novel regulatory pathway for innovative diagnostics may have a favorable impact on test reimbursement in the future. Such valuebased payment arrangements are virtually unheard of in the EU.
The integration of clinical value and realworld evidence demonstration with the process of incor porating medical innovation in patient care in a timely manner is only in its infancy. PM market challenges represent only the latest manifestation of the ongoing struggle of embattled policy makers and regulators attempting to keep pace with medi cal advances and sophisticated technologies. These same decisionmakers are now faced with the crisis brought on by new budget constraints and global financial challenges, and some, such as in the UK, are responding with strong austerity measures.
How can societies and national governments organize themselves in an attempt to modern ize and improve the efficiency of healthcare delivery under these conditions? Some innova tors, such as Genomic Health, have presented a partial solution to some of these dilemmasthe Oncotype DX test has demonstrated cost and clinical outcome improvements for patient, provider, payer and society, in the USA, Japan, Israel and Europe. Yet, even with this unique information set, and realworld cost offsetting demonstration, many policymakers remain unconvinced, and European market penetra tion, as described later in this article, is minimal.
What does this mean for diagnostic compa nies and others at the frontier of attempting to improve the quality of care in Europe?
In this article, the authors, several of whom are also founders of The European Personalized Medicine Coalition (EPEMED), grapple with the challenges of market access and improving patient care across the European community. Regulatory and reimbursement practices in the major European markets are reviewed, and con sideration given to some specific test scenarios. The article will argue that, while barriers to rapid adoption of PM exist in both the USA and the EU, additional barriers and complexity are faced in the EU context. As will be seen later in this article, several of the major European nations have highly complex reimbursement systems.
Market access in the EU
n Potential hurdles to market access in the EU The EU currently comprises 27 member states, illustrated in Figure 2 . The attached Adapted with permission from [3, 6, 7] .
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UK
The UK is considered in detail here, as it has perhaps the best developed technology evalu ation and medico-economic assessment sys tem exemplified by the practices of NICE. Nevertheless, as with several other European countries (Figure 3 ), in contrast to the process for drug approval and reimbursement evaluation, the technical assessment process for diagnostics in the UK remains somewhat decentralized and lacks transparency. Until recently, there was no single HTA group responsible for the evalua tion of diagnostic testing for common diseases. However in 2010, NICE was charged with the evaluation of diagnostics [102] . The scope and nature of its i nvolvement and requirements are yet to be determined. For technologies that are still not evaluated by NICE, the manufacturer must submit support ing evidence to local budget holders, which may apply different criteria for acceptance. Strong emphasis is on physician and hospitallevel deci sionmaking regarding test adoption and budget impact. As discussed previously, CEmarked diagnostic tests are brought to market under the common EU in vitro device directive require ments (98/79/CE). In the UK, there are two options to obtain competent authority regula tory acceptance: either through selfcertification by the manufacturer or conformity assessment made by a notified body (e.g., Medicines and Healthcare Products Regulatory Agency). The latter process is usually applied for the high risk tests typical of many PM scenarios. Currently, the evaluation focuses on assessment of test per formance and budget impact, while there are only limited requirements to demonstrate change in patient management or impact on health out comes by applying a test. Changes in require ments for clinical and economic impact are, however, evolving. In the 'Report of Genomic Medicine, House of Lords 2008-2009 [103] it is stated: "The [process for] evaluation of genomic tests contrasts with the evaluation system for new drugs which pass through a rigorous inde pendent evaluation within NICE to assess their utility, validity and cost-effectiveness. At pres ent, genetic tests for singlegene disorders are evaluated by the UK Genetic Testing Network (UKGTN) [104] . The UKGTN is a collaborative group of National Health Service (NHS) labo ratory scientists, clinical geneticists, NHS com missioners and patient representatives. Tests that pass the UKGTN evaluation process, the 'Gene Dossier Process', are recommended for NHS funding. The UKGTN system works well for tests for singlegene disorders (e.g., Gaucher dis ease and cystic fibrosis). By contrast, it is unclear how genomic tests for common diseases, includ ing pharmacogenetic and microarraybased tests, are evaluated".
Only in rare exceptions (mainly for compan ion diagnostics, a subset of PM tests) does NICE conduct HTAs, while in general, diagnostic evidence is instead submitted by test manufac turers to individual budget holders, followed by negotiation of test reimbursement and payment tariffs. Reimbursement negotiations for compan ion drug/diagnostic products follow the typical pathway for drug reimbursement and pricing. Where appropriate and acceptable to payers and manufacturers, risksharing agreements are increasingly applied. NICE reviews clinical and economic evidence and gives recommendations on reimbursements for NHS decisions. Although not explicitly mandatory for single diagnostics, health economic modeling will likely be required to support complex molecular diagnostics.
The companion tests for Herceptin and Erbitux are the current examplars in patient stratification to establish personalized treat ments. Prior to NICE assessment of relevant drugs, the pharmaceutical sponsors paid for diagnostics (Roche [Basel, Switzerland] In addition to the aforementioned institu tions new diagnostic approval developments will also be influenced by the UK Technology Strategy Board stratified medicines innovation platform [105] . It should also be noted that the role of NICE within the UK healthcare system is currently in flux.
While HER2, EGFR and KRAS testing are now reimbursed on costbased formulae in the UK, such approvals took several years and ben efitted from the interim direct sponsorship of the pharmaceutical owners of the drugs in question. Such costbased approaches do not provide the necessary reward for medical innovation, and it is unclear whether the scenarios described earlier are scalable, can be replicated without pharma sponsors or provide timely patient access in general.
Germany
Germany is the biggest EU diagnostics market. Similar to all countries, it is struggling to intro duce new technologies and to contain costs of its healthcare system. To access the market with a diagnostic product, several groups are involved, which makes successful general introduction a lengthy process.
As described earlier, products require a CE mark. In addition, medical opinion leaders define required analytical performance, clinical utility and health-economic benefit. Medical doctors support and promote the use of a test. Advocacy groups and politicians may be helpful to support reimbursement.
In Germany, approximately 88% of the popu lation is covered by the public insurance system and 12% by a private insurance or on a selfpay basis. The reimbursement by the public system is moderate. Private insurance may reimburse ser vices and products that are not covered by the public system and payments tend to be higher. As shown in Figure 4 , public system reimbursement decisions are made by a committee (Common Health
to assess therapies and diagnostic meth ods on quality, health and economic benefit, according to its own developed methods. The total process has no specific timelines. IQWiG receives requests from GBA but can also start its own assessments, but only GBA can implement those. As highlighted in Innovative tests are introduced often as LDTs. Particularly in oncology and genetic diseases, a majority of tests, including HER2 and KRAS, are performed using laboratory developed research use only reagents (even when a CE marked prod uct exists) and reimbursed in Germany by a CPT codelike process, thus by technical p rocedure cost and not clinical or e conomic value.
France
France is the second market in Europe for drugs, behind Germany. However, despite a very effec tive cost containment policy owing to a central ized control of drug budget impact from the French Ministry of Health, there is further potential for highvalue diagnostics to increase pressure on drug manufacturers while capturing a part of the expected savings.
Haute As a consequence of the KRAS and other highvalue diagnostic market access experi ence, payers in France have clearly understood the interest of diagnostic tests for personal ized treatments, in order to increase benefits to patients, but also from their own payer's per spective. This is why the Nomenclature Générale des Actes Professionnels coding system is being replaced by the Classification Commune des Actes Médicaux (CCAM) coding system, potentially providing for a direct review by the CNEDIMTS of new diagnostic technolo gies leading to coverage. This change in coding policy could also improve simultaneous assess ments by TC and CNEDIMTS for the drug and its associated diagnostic, respectively, resulting in a better recognition of the added value of the global combined therapeutic-diagnostic offer ing. Such a scenario might also have benefited herceptin, for which testing was first authorized in 2000, but for which reimbursement has been provided only since 2007.
IQWiG is a scientific institute that provides evidence-based technology assessments on behalf of the G-BA KBV represents the ∼150,000 contract outpatient physicians. Each of the 17 regional KV manages budget and provision of care for their region G-BA issues binding directives that must be followed by both healthcare providers and sickness funds, and has the general authority to exclude or rationalize statutory medical benefits within the German healthcare system Public health insurance (SHI/GKV) covers ∼88% of the German population. In total, 75% of the population is required to be enrolled, while 14% has opted in. Private health insurance covers the remaining 12% of the population Market access challenges for high medical value diagnostic tests White PaPer
Spain
In Spain, a decentralized model applies in which the 17 autonomous regions and two auto nomous cities are responsible for the delivery and financing of healthcare. National coordi nation amongst these regions is managed via the National Health System Interterritorial Council, chaired by the National Health Minister. This council establishes mandatory care levels that must be provided by all the regions. In 2003, regulations were introduced (Law of Cohesion and Quality of the National Health System) mandating inclusion of new technologies in the national catalog after specific review of efficacy, cost, efficiency, effectiveness, safety and thera peutic utility of the different alternatives. The council makes decisions relating to inclusion of products and services, but the central govern ment representatives are responsible for pricing decisions. A HTA is required when incorporat ing new techniques, technologies or procedures, or when excluding those already provided, in the national common benefit package. The evalua tion is carried out by the national HTA agency When marketing authorization is granted, the Ministry of Health initiates a procedure to decide on reimbursement of this new product on the national reimbursement list. The manufac turer is then invited to provide all relevant infor mation to allow the InterMinisterial Pricing Commission (La Comisión Interministerial de Precios de los Medicamentos), led by Ministry of Health, to make a decision. If the outcome is positive (inclusion in the national reimburse ment list), this decision is valid (mandatory) throughout the country.
Few personalized medicine tests have gone through this process. Instead, tests such as HER2 and KRAS are sometimes supported by the phar maceutical companies whose drugs they indicate (Roche for HER2 and Merck kGA for KRAS), but more typically are paid out of the hospital budget. As will be discussed again later in this article, this paradigm has effectively deferred www.futuremedicine.com availability of high medical value PM tests, espe cially when not used as true co mpanion tests for a pharmaceutical product.
Italy
The Italian healthcare system is a decentralized version of the British NHS. Since 1978, there is a universal Healthcare system (Servizio Sanitario Nazionale) covering the whole population with national universal and compulsory health insur ance. In Italy, therefore, it is not possible to opt out of the Servizio Sanitario Nazionale. Patients are free to choose between public or private pro viders for many healthcare services. Since it is pos sible for the public sector to outsource the delivery of medical health services, an increasingly large part of healthcare services are currently pro vided by accredited private providers. Moreover, patients are free to buy private health insurance and to receive treatment at non contracted private hospitals or consult private outpatient specialists, at their own expense. As in other European coun tries with increased personal income levels, more individuals choose to supplement their public health insurance with the purchase of personal health insurance, in a tiered system. There is a consolidation and optimization of diagnostic laboratory efficiency since 2007 resulting in larger tenders and increasing length of contracts, with a lower budget level. On the regulatory side, Italy has recently dedicated resources exclusively to improve medical vigilance of diagnostic prod ucts. Innovative tests such as HER2 and KRAS are publicly funded and available via a network of public hospital laboratories organized in a network comparable to France.
Nordic countries
Healthcare costs in the Nordic countries (Denmark, Sweden, Norway, Finland and Iceland) are in general covered by their national healthcare systems. In some of the countries, patients cover part of primary care and prescrip tion medicine costs. Expenses related to testing of specimens, for example blood, urine and tis sue biopsies as part of the diagnostic workup of an individual patient as requested by the treating physician are, in general, covered by the national healthcare systems. Personalized medicine tests must be approved by individual regions in each country before phy sicians can offer testing to patients. Some minor differences of approved tests can be seen from region to region. Rationale for i mplementation of a given test will usually be a direct link between test result and a specific treatment. This may be based on inclusion of the test in the drug labeling or on unambiguous recommendations by internationally well established groups such as St Gallen Oncology Conference or the National Comprehensive Cancer Network.
Guidelines for selection of a given test are not established in the Nordic countries although technical validation of internally developed assays is established in all laboratories offering testing of clinical specimens. Commercially available assays having IVDCE labeling are uti lized in the majority of laboratories in order to gain predictive information although some labo ratories might utilize internally developed and validated assays. For HER2 testing, the major ity of test sites are using immuno histochemistry and in situ hybridization assays from commer cial manufacturers. All clinical test laboratories in the Nordic countries participate in national or international proficiency testing programs such as NordiQC [106] and UK NEQAS [107] , although the consequence of performance evalu ation in these programs is limited. Accreditation of the Nordic test laboratories has been initiated with emphasis on turnaround time and logistics.
Case studies of several high-complexity LDTs
In the foregoing discussion, several European market scenarios for the HER2 and KRAS tests were considered. Two further leading examples of personalized medicine tests on the US market today serve to highlight the European market's entry challenges. Both tests are highcomplexity, valuebased priced LDT offerings. Other LDTs will also be considered in this section. The first of these tests to be considered here is the Trofile™ companion test.
Trofile was developed as a companion test for HIV1 coreceptor tropism. This companion test to Maraviroc (brandname Selzentry ® , or Celsentri outside the USA), manufactured by Pfizer (NY, USA), is the result of a collabora tion initiated in 2006 intended to demonstrate tissue tropism, or the cellular route taken by the HIV1 virus to enter CD4 cells. This is the first such collaboration in HIV and, together with KRAS, is probably the most highprofile companion test developed since the HER2 test in 1998. The Trofile assay is used to identify the CCR5tropic patient subpopulation that responds to CCR5 antagonists. When the col laboration began, Pfizer's drug was in Phase III and the assay was used for latestage clinical trial selection. The drug has since been approved for marketing and incorporated in the standard of care for patients identified as CCR5 tropic by the US$1960 Trofile laboratorydevelopedtest (price quoted is launch price rather than current average selling price from provider Labcorp).
Recognition of the barrier to entry for the com plex Trofile assay in Europe forced the partners to structure a deal specifying that Pfizer would pay Monogram for the Trofile test in Europe and other exUS markets. This relatively unusual arrangement was structured to circumvent the significant adoption challenge the drug would otherwise have faced. In the USA, by contrast, the test received nearly 100% of payer coverage within 12 months of launch. While this central ized test offering is also available in the major European markets, it is not directly supported by the European healthcare system. It is unlikely that the Monogram-Pfizer model can be scaled across the whole industry, and not all compan ion test scenarios have a pharmaceutical spon sor. Furthermore, test and drug adoption have been hampered by logistical and marketing chal lenges. In March 2010, Pfizer partnered with US pharmacy benefits manager Medco (NJ, USA) to further build physician awareness. Outside the USA, Pfizer leads reimbursement initiatives for both the drug and the test.
It is also illustrative to consider the example of Genomic Health's Oncotype DX test, launched in the USA in 2004. This prognostic and predic tive assay has been shown to quantify a patient's risk of recurrence in earlystage, nodenegative, estrogen receptorpositive (ER + ) invasive breast cancer and also the likelihood of chemotherapy benefit. This assay examines a small portion of a patient's fixed and paraffinembedded tumor tissue at a molecular level, using quantitative reversetranscriptase (qRT) PCR technology to measure 21 cancerrelated genes and controls, and provides quantitative information about the biol ogy of the individual's disease. The test reports a computed algorithm as a single Recurrence Score™ between 0 and 100 to quantify the likelihood of distant recurrence at 10 years.
The company, collaborators, private payers and a number of other institutions have produced an array of collaborative and independent studies on thousands of patient samples demonstrating a rather robust evidence platform associated with various aspects of the test. There has also been a number of utility trials and health economic studies outlining the clinical ramifications of the test in cancer care. This represents the most robust evidence generation effort for a single indi cation and specific valuepriced diagnostic test, and has driven the test to standardofcare status in the USA, with approximately 50% penetration of initial target market [3] . Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network (NCCN) rec ommend the use of Oncotype DX for patients with breast cancer in their respective clinical practice guidelines.
The company was able to win valuebased pricing in the USA of approximately US$3900, based on its health-economic analyses. Using a 100patient cohort from the US National Surgical Adjuvant Breast and Bowel Project, the company was able to demonstrate a $2000 per patient savings resulting from deployment of the test in the eligible population [4] . In prac tice, oncologists and surgeons can use the recur rence score to determine which patients are most likely to benefit from chemotherapy, thus spar ing those that are not likely to benefit from the side effects, and conserving resources for payers, which is estimated to be $10,000-20,000 on average per patient.
The company currently generates approxi mately $170 million in annual revenue, pri marily from sales of Oncotype DX. However, only approximately 6% of sales are generated outside the USA, and the company has not real ized significant penetration into European mar kets, despite the existence of robust clinical and healtheconomic evidence. Most patients outside the USA pay on an outofpocket basis. By con trast to its USA accessible market penetration of approximately 50%, penetration outside the USA is less than 2% [3] .
While Trofile and Oncotype DX represent leading US examples, they are not unique. Figure 6 shows these assays in the context of other valuepriced offerings in the USA, with 2008 US prices in the range of $1000 to more than $4000. None of these assays have dem onstrated significant market penetration in Europe. For example, XDx (CA, USA) CEO Pierre Cassigneul explained at the October 2010 EPEMED annual conference that the AlloMap ® test was not even being marketed in Europe owing to market complexity, including r eimbursement challenges [108] .
Conclusion
A more personalized approach to medicine is likely to prevail in the years to come, led by more precise diagnostic, prognostic, and com panion predictive and monitoring test offerings. However, with 10-30% of drugs expected to be required to include a companion diagnos tic, the absence of appropriate public sector www.futuremedicine.com reimbursement models is likely to deprive the European population of efficient access to rapidly emerging standard of care therapy.
This article has focused on the two core issues of general reimbursement process in efficiencies in Europe associated with suboptimal proce dure-costbased payment, together with the virtual absence of precedents for the diagnostic valuebased reimbursement necessary to stimu late development. Notably, even procedure based diagnostic payment, while far from an equitable market model, faces inter and intra national hurdles, including lack of health tech nology assessment transparency, decentraliza tion of review and occasionally complete lack of associated funding. This results in access delays and necessitates workarounds such as subsidization by pharmaceutical companies. While each of the European nations considered has ultimately found a way to support two of the leading predictive tests available today on a modest procedurally priced basis, we argue that this has happened in a way which is not scal able and which does not foster efficient growth of the field. Furthermore, as discussed, there is no precedent for European public sector value based test reimbursement, hence cuttingedge valuebased tests are only available to a select few in Europe.
Two current workarounds prevail in Europe. The first involves pharmaceutical subsidization or sponsorship of diagnostic test reimbursement. This has happened with HER2, KRAS, EGFR and BCR-ABL testing with sponsors such as Roche, Novartis (Basel, Switzerland), Merck kGA, Amgen and Astra Zeneca. This may increasingly become the norm for codevelopment programs between pharmaceutical and diagnostic companies, especially when one considers that diagnostics companies, in general, lack the deep reimburse ment core competency of their pharmaceutical partners. However, this solution is probably not scalable and is in any event limited to such predictive collaborations, themselves represent ing only a subset of the universe of PM tests. Another workaround entails the temporary targeting of private sector patients, depriving approximately 90% of the European popula tion of timely access, especially for tests with valueoriented pricing.
Europe, with its primarily centrally man aged healthcare systems, has the potential to be a leader in the emerging PM field. However, current reimbursement practices deter innova tion, much of which is being driven in the USA. To foster local innovation and patient access in the EU, more process clarification, review cen tralization, demonstration models and clarifica tion of economic and other utility criteria will be required.
One example of a useful attempt to foster and rationalize use of European HTA resources is the joint initiative between the European Adapted with permission from [9] .
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Executive summary

Background
Global reimbursement challenges for high-value diagnostics tests are significant. In the USA, while there are several examples of 'value-priced' laboratory-developed tests (LDTs), there are no comparable examples of in vitro diagnostic (IVD) tests. In Europe, however, there is no precedent for public sector value pricing to incentivize high-value diagnostic development for either LDTs or IVDs, and European patients are effectively denied access.
Specific challenges in Europe
Europe presents specific inter-and intra-national heterogeneity in terms of diagnostic reimbursement. The complex European IVD reimbursement paradigm is reviewed for several major markets in this article, and specific challenges for test developers are highlighted. It is noted that diagnostic reimbursement is less centralized and less transparent than its therapeutic counterpart, which has a significant adverse impact on European innovation.
Possible solutions
This article describes several initiatives to address Europe-specific challenges. Several of the authors, in addition to serving in leading personalized medicine companies, are also founders of The European Personalized Medicine Coalition, an emerging European advocacy organization formed to address market challenges.
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